Just in JAMA Network Open 👉 Baseline bone pain associated with ⬇️ survival in mHSPC #prostatecancer (pt level analysis of a SWOG Cancer Research Network ph3 trial) 👇 mHSPC pts w/ bone pain may be prioritized for trials 👉 tinyurl.com/5xa82bt6 Neeraj Agarwal, MD, FASCO GU Cancer Research Program @HuntsmanCancer OncoAlert UroToday.com

Congrats George Georges Gebrael for your work on this patient level analysis of a SWOG Cancer Research Network ph3 trial (n=1313 pts) 👉data warrant inclusion of baseline bone pain in prognostic models in mHSPC #ProstateCancer Cc: University of Utah Department of Internal Medicine Caroline Milne John Inadomi Huntsman Cancer Institute Neeraj Agarwal, MD, FASCO

On my way! Program is busting with goodness. Glad to be attending this meeting. Grateful to the entire organizing committee for putting so much work into this. Well done!

Multimodal AI-Based care of patients with RCC #kidneycancer by Dr. Christopher Weight Cleveland Clinic 👉Using AI to improve outcomes with existing data & personalize RCC Rx👇 #KCRS24 KidneyCAN Toni Choueiri, MD Stephanie Berg Katy Beckermann

Congrats Alejandro Sanchez, MD Huntsman Cancer Institute way to make progress in the fight against kidney cancer! Utah Urology Residency Program

Brilliant insights from Tom Powles Barts Cancer Institute (Queen Mary). Excellent use of Twitter polls to reconcile tough clinical scenarios (eg IO rechallenge following adj pembro). Shocking to hear rates of IO receipt in real world series - great point from Tom - use the best tx first. Toni Choueiri, MD

Emerging treatment options in adjuvant RCC #kidneycancer setting, comprehensive talk by Bradley McGregor Dana-Farber Lank Center for Genitourinary Oncology 👉Principles of adjuvant therapy 👇Kim-1 may allow patient selection and novel ongoing trials👇#KCRS24 KidneyCAN Toni Choueiri, MD David Braun

Another wonderful talk by David Braun on novel immunotherapy treatment of mRCC #kidneycancer 👉Novel ICIs, cytokines, vaccines, and microbiome modulation 👇#KCRS24 KidneyCAN Highlights the microbiome work by Nazli Dizman Sumanta K. Pal, MD, FASCO

Very proud of our mentees Albert Jang, MD & Jeffrey Zhon who just won merit award at KCRS tackling long term responses with IO combos using pseudo individual patient data (IPD) paper 2 follow! Sumanta K. Pal, MD, FASCO Rana McKay, MD, FASCO University Hospitals Kidney Cancer JAGarciaMD Jason Brown #KCRS24

Small study but should be very helpful in understanding the component effects from the ongoing combination studies.

More evidence that PD(L)1 re-challenge should be avoided in renal cancer. Tivozanib+ Nivo showed no ⬆️ in efficacy v.s Tivo alone in PD(L)1 pretreated RCC pts. ⬇️ Tivo dose in study arm requires consideration. This has implications post adjuvant pembro prnewswire.com/news-releases/…

More awesome news for patient with mCRPC --> combo enza + radium-223 superior to enza alone. PEACE III. Press Release here: eortc.org/blog/2024/07/1… This leverages on prior work from Neeraj Agarwal, MD, FASCO Dr Neal Shore and others Benjamin L Maughan Sumanta K. Pal, MD, FASCO Rana McKay, MD, FASCO Tanya Dorff Emmanuel Antonarakis

Just in JAMA Network Open 👉 Unacceptablely low rates of NGS testing in metastatic #ProstateCancer #bladdercancer in real world pts (worse in Black & Hispanic pts)Flatiron Health👇Proud of our postdoc, Chadi Chadi Hage Chehade , Yeonjung @yeonjungjohci, George Georges Gebrael & team👇

🎉We congratulate the 12 leaders selected for the 2024-2025 Leadership Development Program (LDP), & we encourage those interested in shaping the future of oncology to apply for the 2025-2026 LDP; applications are currently open: brnw.ch/21wLqSG #OncTwitter #MedTwitter

(1/4) Tweetorial for our latest paper on body composition’s influence on the therapeutic index with ARSI in Prostate Cancer and Prostatic Diseases shorturl.at/UFqay This work was supported by a Conquer Cancer, the ASCO Foundation YIA and established our ongoing research program MD Anderson Cancer Center

Happy birthday to Dr. Nizar Tannir MD Anderson Cancer Center, one of our longest-serving Medical Steering Committee members. Thank you for everything you do, have an amazing day!

Happy birthday Nizar on turning 45! 🎂

Just in👉bit.ly/3Wygodg One of the largest real world studies evaluating trt trends in #nmCRPC found underutilization of NHT even 2 years after approval. ADT and ADT+NSAA remained most common trt. Prostate Cancer Foundation UroToday.com OncoAlert #prostatecancer

Dr. Heath Elisabeth Heath gives an excellent overview of ongoing ph3 trials of Lutetium-177 with various carrier molecules in metastatic #prostatecancer at the #WorldGU24 World GU Conference 👉RLTs are moving upstream, various carriers of Lu-177👇UroToday.com OncoAlert

Another stellar talk by David Braun in #Worldgu24 World GU Conference 👉How to diagnose RCC #kidneycancer pts with residual disease after surgery? 👉liquid epigenomic profiling, CTCs (shoutout to the great Josh Lang ), Kim-1 and more👇 KidneyCAN UroToday.com OncoAlert